What is IPO Grey Market Premium (GMP)?

IPO Grey Market Premium (GMP) is an unofficial, over-the-counter premium over the issue price that dealers and investors pay prior to official listing on NSE/BSE.

How is estimated IPO listing price determined?

Estimated Listing Price = Cut-off / Issue Price + Current Grey Market Premium (GMP). For example, an issue price of ₹100 with ₹40 GMP yields an estimated listing price of ₹140 (+40%).

What is Kostak rate in an IPO?

Kostak rate is the fixed profit earned by selling an IPO application before allotment, irrespective of whether the application is allotted shares or not.

What is Subject to Sauda in IPO trading?

Subject to Sauda is an informal contract where payment is made only if the seller receives share allotment in the IPO.

Is IPO Grey Market Premium (GMP) regulated by SEBI?

No. Grey Market transactions are non-exchange over-the-counter commitments and are not officially regulated or endorsed by SEBI. Investors should treat GMP as an informal sentiment indicator.

What is the current subscription status of Glenmark Life Sciences Limited IPO?

Glenmark Life Sciences Limited IPO has received a total subscription of 0.00 times overall.

IPO GreyPremiumLIVE

Grey Market Intelligence

Glenmark Life Sciences Limited

ListedMainboard

Healthcare & Pharmaceuticals · NSE / BSE

Incorporated in 2011, Glenmark Life Sciences is a leading manufacturer of active pharmaceutical ingredients (APIs), developing and supplying high-quality products used in treatments for cardiovascular, central nervous system, pain management, diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. The company serves customers in India and exports its products to several international markets including Europe, North America, Latin America, and Japan. It operates four manufacturing facilities located at Ankleshwar and Dahej in Gujarat, and Mohol and Kurkumbh in Maharashtra, with a total annual installed capacity of 725.8 KL as of December 31, 2020.

Price Band

₹695 – ₹720

Issue Size

₹1514 Cr

Lot Size

20 shares

GMP

₹82

+11.4%

Est. Listing

₹802

at current GMP

Subscribed

—

Open

27 Jul 2021

29 Jul 2021

Allotment

3 Aug 2021

Refund

4 Aug 2021

Demat Credit

5 Aug 2021

Listing

6 Aug 2021

Last updated 12 days ago

Overview Live GMP Subscription Status Allotment Status Filing Documents

Overall Subscription

0.00x

Total Demand

QIB Multiplier

0.00x

Institutions & Funds

NII / HNI

0.00x

High Net-Worth

Retail (RII)

0.00x

Individual Bidders

Category-Wise Subscription Breakup

Live bidding breakdown by institutional, non-institutional, and retail investors

Total 0.00x

Category	Shares Offered	Shares Applied / Bid	Times Subscribed
Qualified Institutional (QIB)	10,513,889	—	0.00x
Non-Institutional (NII / HNI)	3,154,167	—	0.00x
Retail Individual (RII)	7,359,722	—	0.00x
Total	21,027,778	0	0.00x

Application-Wise Breakup

Total unique applications received across retail and HNI tranches

Apps 1.00x

Category	Applications Reserved	Applications Received	Times Subscribed
Retail (RII)	367,986	367,986	1.00x
HNIs (10L +)	2,354	2,354	1.00x
HNIs (2-10L)	11,265	11,265	1.00x
Total Applications	381,605	381,605	1.00x

Day-Wise Subscription Progress

Track continuous institutional and retail bidding order books for all active issues on the ipo live subscription feed.

About Glenmark Life Sciences Limited Public Issue & Market Profile

Glenmark Life Sciences Limited is bringing an initial public offering (IPO) in the Healthcare & Pharmaceuticals sector with an aggregate issue size of ₹1,514 Crores. The shares are offered at a price band of ₹695 to ₹720 per equity share on NSE and BSE. Currently, traders and retail applicants are calculating expected listing gains and break-even points based on unofficial grey market quotations.

Bidding & Quota Instructions:

Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 20 shares (approx. ₹14,400 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.

Allotment Reconciliation Schedule:

Allotment reconciliation will be managed by Kfin Technologies Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2021-08-05, while un-allotted funds or UPI block mandates will be released on 2021-08-04.

Frequently Asked Questions

What is Glenmark Life Sciences Limited IPO GMP today?

The latest Grey Market Premium (GMP) for Glenmark Life Sciences Limited IPO is ₹82 per equity share. Based on the upper price band of ₹695 to ₹720 per equity share, the estimated listing price is ₹802 (+11.4% expected listing gain).

What is the expected profit per lot for Glenmark Life Sciences Limited IPO?

With a lot size of 20 shares and current GMP of ₹82, the expected profit per application lot is approx ₹1,640 (+11.4% gain). Minimum application cost is approx ₹14,400.

What is the issue size and price band for Glenmark Life Sciences Limited IPO?

The Glenmark Life Sciences Limited IPO aggregate issue size is ₹1,514 Crores with an equity price band set at ₹695 to ₹720 per equity share. The retail lot size is 20 shares requiring a minimum capital outlay of approx. ₹14,400.

How can I check Glenmark Life Sciences Limited IPO live subscription demand?

Live subscription figures are compiled real-time from the NSE and BSE bidding engines. Currently, overall subscription is 0.00x (Retail: 0.00x, QIB: 0.00x, NII: 0.00x). You can track live multiples directly on our dedicated subscription page.

Where and when will Glenmark Life Sciences Limited IPO allotment status be published?

The basis of allotment will be published on the official registrar portal (Kfin Technologies Limited) and the BSE status verification website on or around 2021-08-03. Investors can verify status using PAN card or application number.

When is the listing date for Glenmark Life Sciences Limited IPO?

Glenmark Life Sciences Limited shares are scheduled to list on NSE and BSE on 2021-08-06.